Key Points
- Alpha Tau Medical CFO Raphi Levy sold 17,500 shares on June 23 at an average price of $9.55, generating about $167,125. The sale was made under a pre-arranged Rule 10b5-1 plan.
- After the transaction, Levy still held 130,180 shares, and the sale represented an 11.85% reduction in his position. He also sold 32,500 shares earlier in June at an average price of $10.83.
- The company recently reported a quarterly EPS loss of $0.26, worse than the expected loss of $0.13, while analysts currently have a Hold consensus rating with a $12.60 price target.
Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) CFO Raphi Levy sold 17,500 shares of the company's stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $9.55, for a total transaction of $167,125.00. Following the completion of the sale, the chief financial officer owned 130,180 shares in the company, valued at approximately $1,243,219. This trade represents a 11.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Raphi Levy also recently made the following trade(s):
- On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total transaction of $351,975.00.
Alpha Tau Medical Price Performance
DRTS stock opened at $11.17 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.79 and a current ratio of 7.79. The firm has a 50 day moving average price of $9.33 and a 200-day moving average price of $7.59. Alpha Tau Medical Ltd. has a 52-week low of $2.87 and a 52-week high of $11.62. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -16.67 and a beta of 1.19.
Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last posted its quarterly earnings results on Monday, May 18th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.13). Equities research analysts forecast that Alpha Tau Medical Ltd. will post -0.67 EPS for the current fiscal year.
Hedge Funds Weigh In On Alpha Tau Medical
Hedge funds have recently bought and sold shares of the business. Daytona Street Capital LLC bought a new stake in shares of Alpha Tau Medical in the fourth quarter worth approximately $749,000. Apella Capital LLC bought a new position in Alpha Tau Medical during the fourth quarter valued at approximately $1,892,000. Millennium Management LLC boosted its holdings in Alpha Tau Medical by 185.7% in the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company's stock worth $534,000 after purchasing an additional 70,081 shares during the last quarter. Mariner LLC boosted its holdings in Alpha Tau Medical by 1.6% in the fourth quarter. Mariner LLC now owns 125,165 shares of the company's stock worth $620,000 after purchasing an additional 1,915 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company's stock worth $116,000 after purchasing an additional 17,500 shares during the last quarter. Hedge funds and other institutional investors own 2.65% of the company's stock.
Analysts Set New Price Targets
Several brokerages have recently weighed in on DRTS. Weiss Ratings restated a "sell (d-)" rating on shares of Alpha Tau Medical in a report on Monday, April 20th. LADENBURG THALM/SH SH upped their target price on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Tuesday, May 12th. Citigroup increased their price target on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, March 11th. Piper Sandler raised their price target on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a "neutral" rating in a research report on Tuesday, May 19th. Finally, Barclays upped their price objective on Alpha Tau Medical from $15.00 to $17.00 and gave the company an "overweight" rating in a research report on Thursday, June 4th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $12.60.
View Our Latest Analysis on Alpha Tau Medical
About Alpha Tau Medical
(
Get Free Report)
Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.
The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
